

## EFFECTS OF $\alpha$ -TOCOPHEROL ON CARBON TETRACHLORIDE METABOLISM IN RAT LIVER MICROSOMES

K.H. CHEESEMAN<sup>†</sup>, M.J. DAVIES, S. EMERY, S.P. MADDIX and T.F.  
SLATER

*Department of Biochemistry, Brunel University, Uxbridge UB8 3PH, UK.*

*(Received June 23rd 1986)*

$\alpha$ -tocopherol is the major lipid-soluble radical-scavenging antioxidant in rat liver. It has long been used as a putative protective agent in  $\text{CCl}_4$  induced liver injury but with variable results. We have used  $\alpha$ -tocopherol loaded rat liver microsomes to study the effect of this vitamin on  $\text{CCl}_4$  metabolism *in vitro*. As expected,  $\alpha$ -tocopherol inhibits  $\text{CCl}_4$ -dependent microsomal lipid peroxidation and, at a very high concentration, will inhibit the covalent binding of  $\text{CCl}_3\cdot$  to microsomal protein by up to 50%. No inhibitory effect was observed towards  $\text{CCl}_3\cdot$  production as measured by the electron spin resonance technique of spin-trapping but this apparent discrepancy may represent a limitation of the technique. The high levels required to inhibit covalent binding probably preclude the likelihood of  $\alpha$ -tocopherol significantly affecting that phenomenon at endogenous concentrations but may be relevant to other experiments employing high doses of  $\alpha$ -tocopherol as an experimental hepatoprotective agent.

KEY WORDS:  $\alpha$ -tocopherol, carbon tetrachloride, lipid peroxidation, covalent binding, spin-trapping.

### INTRODUCTION

Administration of carbon tetrachloride ( $\text{CCl}_4$ ) to a rat produces centrilobular necrosis and fat accumulation in the liver. This hepatotoxicity of  $\text{CCl}_4$  is dependent upon its metabolism by the cytochrome P-450 system of the endoplasmic reticulum to a reactive intermediate, the trichloromethyl free radical,  $\text{CCl}_3\cdot$ .<sup>1,2</sup> Subsequent to this activation step, peroxidative degradation of the polyunsaturated fatty acids of the endoplasmic reticulum is initiated and metabolites of  $\text{CCl}_4$  bind covalently to membrane lipids and proteins. It is now considered that  $\text{CCl}_3\cdot$  is largely responsible for the covalent binding to macromolecules and that the more electrophilic trichloromethylperoxyl free radical ( $\text{CCl}_3\text{O}_2\cdot$ ), which is produced from  $\text{CCl}_3\cdot$  extremely rapidly under aerobic conditions, is the intermediate responsible for initiating  $\text{CCl}_4$ -dependent lipid peroxidation.<sup>2</sup> The respective roles of covalent binding and lipid peroxidation in  $\text{CCl}_4$ -induced liver damage have long been a matter of debate and it is now generally held that both processes are of major significance.<sup>1,3</sup>

The effects of antioxidants on  $\text{CCl}_4$ -induced liver injury have been studied over many years in attempts to confirm the role of lipid peroxidation in  $\text{CCl}_4$  hepatotoxicity and to discriminate between cytotoxic phenomena linked to that process and those linked to binding.<sup>1,3</sup> The major lipid-soluble radical-scavenging antioxidant of the hepatic endoplasmic reticulum is  $\alpha$ -tocopherol<sup>4</sup> and this compound has been tested

<sup>†</sup> To whom correspondence should be addressed.

$\text{CCl}_4$  liver injury in experiments over the last 35 years.<sup>1</sup> The results have been equivocal and the considerable variety of methods used has made comparisons extremely difficult. The most recent data on this topic are those of Corongiu *et al.*<sup>5</sup> and Poli *et al.*<sup>6</sup> each of whom used an identical technique of  $\alpha$ -tocopherol pre-treatment that results in a large hepatic concentration of the vitamin. Corongiu *et al.* confirmed that  $\alpha$ -tocopherol inhibits  $\text{CCl}_4$ -induced lipid peroxidation *in vivo*.<sup>5</sup> Poli *et al.* showed that isolated hepatocytes from  $\alpha$ -tocopherol pre-treated rats were protected from  $\text{CCl}_4$ -induced cell death and lipid peroxidation whilst having identical levels of covalently bound  $\text{CCl}_4$  metabolites to control cells.<sup>6</sup> Moreover,  $\alpha$ -tocopherol dosed rats were protected from  $\text{CCl}_4$ -induced liver necrosis, as measured by leakage of liver cell enzymes into the plasma, for at least 24 h. We have used the same  $\alpha$ -tocopherol dosing regime to produce rat liver microsomes considerably enriched in  $\alpha$ -tocopherol and show that if high concentrations of the vitamin are present then it is capable of inhibiting not only  $\text{CCl}_4$ -induced lipid peroxidation but also the covalent binding of  $\text{CCl}_4$  metabolites to microsomes *in vitro*.

## METHODS

Male Wistar rats, body wt. 200–250 g (Charles River Ltd., Margate, UK) were used throughout. Where appropriate, rats were dosed with  $\alpha$ -tocopherol (100 mg/kg body wt., i.p.) as described by Pfeifer and McCay<sup>7</sup> 16 h before sacrifice and at the same time food was removed from both controls and treated animals. Liver microsomes were prepared as described previously<sup>8</sup> and washed once by resuspension and recentrifugation in 0.1 M Tris: HCl, pH 7.4. The washed pellets were stored for 1–3 days at  $-70^\circ\text{C}$  before the assays were carried out when they were resuspended in 0.15 M KCl such that one ml was equivalent to one gram wet weight of liver.  $\text{CCl}_4$ -stimulated lipid peroxidation (malonaldehyde production) and the covalent binding of [ $^{14}\text{C}$ ]- $\text{CCl}_4$  to microsomal protein were determined simultaneously by incubating microsomes and [ $^{14}\text{C}$ ]- $\text{CCl}_4$  (Amersham International, Amersham, UK) with a source of NADPH aerobically at  $37^\circ\text{C}$  as previously described<sup>9,10</sup> except that an incubation time of 10 mins was used. Malonaldehyde was determined in the protein-free supernatant<sup>9</sup> and irreversibly-bound [ $^{14}\text{C}$ ]- $\text{CCl}_4$  measured in the protein pellet after solvent washing.<sup>10</sup> Using an essentially identical incubation medium, the  $\text{CCl}_3\cdot$  radical was trapped with 15 mM  $\alpha$ -phenyl-N-tert-butyl nitron (PBN) and the adduct extracted into toluene (0.5 volumes) after 5 min incubation under hypoxic conditions. After a brief centrifugation ( $800\text{g} \times 5\text{mins}$ ), the toluene layer was analysed by electron spin resonance spectrometry at  $-70^\circ\text{C}$  using a Bruker ER200D X-band spectrometer operating with 100 kHz modulation, and a Bruker ER411VT variable temperature unit.

Ethoxycoumarin deethylase was measured as previously described<sup>11</sup> but omitting ethanol. NADPH/ADP-iron-stimulated lipid peroxidation was measured as oxygen consumption as previously.<sup>12</sup> Microsomal  $\alpha$ -tocopherol was extracted and measured essentially as described by Burton *et al.* for liver homogenates<sup>13</sup> with some modification. One ml of microsomal suspension (20 mg protein) was mixed with one ml of sodium dodecyl sulphate (50 mM) followed by two mls of absolute ethanol; one ml of n-heptane was added and the sample was vortex-mixed for 1–2 mins. After a brief centrifugation, the n-heptane layer was taken for analysis by HPLC. Samples (100  $\mu\text{l}$ ) were applied to an S5-nitrile column (25 cm  $\times$  4.6 mm; Anachem Ltd., Luton, UK);

TABLE I

Effect of  $\alpha$ -tocopherol dosing on CCl<sub>4</sub> metabolism, lipid peroxidation and ethoxycoumarin deethylase activity in rat liver microsomes *in vitro*

Parameter	Control	Treated
$\alpha$ -tocopherol (nmols/mg protein)	0.5 $\pm$ 0.1 (6)	6.5 $\pm$ 3.0* (6)
CCl <sub>4</sub> -stimulated MDA production (nmols/mg/10 min)	3.98 $\pm$ 1.35 (6)	0.41 $\pm$ 0.64* (6)
Covalent binding of [ <sup>14</sup> C]-CCl <sub>4</sub> to protein (nmols/mg/10 min)	2.6 $\pm$ 0.4 (6)	1.3 $\pm$ 0.4* (6)
CCl <sub>3</sub> -spin trapping (signal height)	17.5 $\pm$ 4.8 (6)	23.3 $\pm$ 5.6** (6)
Ethoxycoumarin deethylase (nmols/mg/min)	0.27 $\pm$ 0.06 (6)	0.23 $\pm$ 0.05** (4)
Induction period, NADPH/ADP-Fe-stimulated lipid peroxidation (mins)	0.6 $\pm$ 0.3 (6)	> 30 (6)

Values are mean  $\pm$  standard deviation with number of animals in parentheses.

Treated animals received 100 mg/kg  $\alpha$ -tocopherol i.p. as described in Methods.

\*  $P < 0.001$ ; \*\* N.S. (student's *t* test)

the mobile phase was hexane:isopropanol (99:1, v/v) pumped at 1.8 ml/min and the U.V. detector was set at 295 nm. The concentrations of  $\alpha$ -tocopherol were determined by reference to injections of standard solutions of  $\alpha$ -tocopherol and by use of a LDC CI10B computing integrator. Microsomal protein was determined by the method of Lowry *et al.*<sup>14</sup>

## RESULTS AND DISCUSSION

Pre-treatment of rats with  $\alpha$ -tocopherol at 100 mg/kg body wt. according to the method of Pfeifer and McCay<sup>7</sup> results in considerable enrichment of hepatic microsomal  $\alpha$ -tocopherol. On average, the liver microsomes of the treated rats contained 13 times more  $\alpha$ -tocopherol than those of the control rats (Table I), but this figure conceals considerable variation in the degree of loading (5-fold to 20-fold). For this reason, an analysis of the precise concentration of microsomal  $\alpha$ -tocopherol actually achieved is to be recommended when using this method. However, while the variability of  $\alpha$ -tocopherol loading may be sometimes inconvenient, this method is certainly much less problematic than attempts to add  $\alpha$ -tocopherol to microsomes (or hepatocytes, liver mitochondria etc) by various methods *in vitro*.<sup>15</sup>

Loading with  $\alpha$ -tocopherol strongly depresses microsomal lipid peroxidation induced by the NADPH/ADP-iron system as measured by MDA production<sup>7</sup> or by oxygen consumption,<sup>4</sup> (Table I) with the latter method providing a convenient and rapid check for  $\alpha$ -tocopherol incorporation. In the present study, CCl<sub>4</sub>-stimulated lipid peroxidation was decreased by  $\alpha$ -tocopherol dosing to about 10% of control levels. Lipid peroxidation dependent upon NADPH (in the absence of CCl<sub>4</sub> or ADP-iron) was inhibited to a similar degree (data not shown). In all these microsomal lipid peroxidation systems the principal action of  $\alpha$ -tocopherol is to act as a chain-breaking antioxidant, scavenging lipid peroxy radicals and being consumed in the process.<sup>16</sup> In the CCl<sub>4</sub> system,  $\alpha$ -tocopherol could also scavenge the proposed initiating radical CCl<sub>3</sub>O<sub>2</sub> $\cdot$  with which it reacts extremely rapidly ( $k = 5 \times 10^8 \text{ M}^{-1} \text{ sec}^{-1}$ ),<sup>17</sup> though the greater relative concentration of fatty acids, with which CCl<sub>3</sub>O<sub>2</sub> $\cdot$  also reacts extremely rapidly ( $k = 2 - 7 \times 10^6 \text{ M}^{-1} \text{ sec}^{-1}$ )<sup>18</sup>

may make the reaction between  $\text{CCl}_3\text{O}_2\cdot$  and  $\alpha$ -tocopherol an inefficient competitive process. As well as inhibiting  $\text{CCl}_4$ -stimulated lipid peroxidation in microsomes *in vitro*, this method of  $\alpha$ -tocopherol dosing also inhibits  $\text{CCl}_4$ -induced lipid peroxidation in liver endoplasmic reticulum *in vivo*, as shown by second derivative spectroscopy of diene conjugates by Corongiu *et al.*<sup>5</sup>

Measurement of the covalent binding of [ $^{14}\text{C}$ ]- $\text{CCl}_4$  to microsomal protein is probably the most reliable quantitative index of  $\text{CCl}_3\cdot$  production.<sup>2</sup> In this study,  $\alpha$ -tocopherol enrichment of the microsomes inhibited covalent binding to protein by 50%. This degree of inhibition was approximately the same in microsomes containing 4.5 nmol/mg protein  $\alpha$ -tocopherol as in microsomes containing more than double this level and may thus represent the maximum achievable inhibition of this parameter by  $\alpha$ -tocopherol. In studies with isolated hepatocytes loaded with  $\alpha$ -tocopherol by the same technique used here, Poli and colleagues have found no effect on the covalent binding of [ $^{14}\text{C}$ ]- $\text{CCl}_4$  to whole cell protein, relative to hepatocytes from control animals.<sup>6</sup> Whether this discrepancy is a function of the different systems (microsomes versus whole cells) or due to a lower level of  $\alpha$ -tocopherol incorporation into the cell membranes in the hepatocyte study can only be a matter of speculation. No effect of  $\alpha$ -tocopherol pretreatment on the covalent binding of [ $^{14}\text{C}$ ]- $\text{CCl}_4$  to liver microsomal lipids *in vivo* was found by Benedetti *et al.*<sup>19</sup> Clearly, it is difficult to compare data with the present study and it may be of interest in the future to compare the effect of  $\alpha$ -tocopherol on covalent binding of [ $^{14}\text{C}$ ]- $\text{CCl}_4$  to lipid and to protein.





Determination of  $\text{CCl}_3\cdot$  production by measurement of the concentration of PBN- $\text{CCl}_3$  adduct by ESR spectrometry showed poor correlation with either  $\text{CCl}_4$ -stimulated lipid peroxidation or with covalent binding, and loading of microsomes with  $\alpha$ -tocopherol did not consistently modify the quantity of spin adduct formed. McCay and colleagues have reported that  $\alpha$ -tocopherol pretreatment enhances  $\text{CCl}_3$ -PBN adduct formation *in vivo*, probably by protecting the enzymes responsible for  $\text{CCl}_3\cdot$  production from inactivation.<sup>20</sup>

In the present study there was an apparent increase in spin adduct formation in the  $\alpha$ -tocopherol-loaded microsomes but this was not statistically significant. Previous studies in this laboratory<sup>21</sup> demonstrated a concentration-dependent reduction in the amount of  $\text{CCl}_3$ -PBN adduct when  $\alpha$ -tocopherol was added *in vivo* to isolated hepatocytes but this may have been due to direct reduction of the spin adduct.

It seems unlikely that  $\alpha$ -tocopherol loading actually diminishes the rate of  $\text{CCl}_4$  activation of  $\text{CCl}_3\cdot$  since the overall activity of the P-450 system, as evidenced by ethoxycoumarin deethylase activity, is unchanged by this treatment.

The above results seem to indicate that  $\alpha$ -tocopherol, in addition to inhibiting  $\text{CCl}_4$ -stimulated lipid peroxidation by scavenging lipid peroxy radicals may inhibit covalent binding of [ $^{14}\text{C}$ ]- $\text{CCl}_4$  by scavenging  $\text{CCl}_3\cdot$  radicals. The rate constant for the reaction of  $\alpha$ -tocopherol with  $\text{CCl}_3\cdot$  is low ( $< 10^5 \text{ M}^{-1} \text{ sec}^{-1}$ ) and one might expect, as indeed seems the case, that  $\alpha$ -tocopherol would need to be present at very high concentrations to compete with membrane proteins for this radical. Therefore physiological concentrations of  $\alpha$ -tocopherol are unlikely to significantly modify the course of this process. The inability of  $\alpha$ -tocopherol to decrease  $\text{CCl}_3$ -PBN adduct formation is probably due to the high concentration in the system of PBN (15 mM) which effectively competes with the vitamin for  $\text{CCl}_3\cdot$ .

An alternative explanation for the inhibition of covalent binding is that  $\alpha$ -tocopherol "repairs" a  $\text{CCl}_3$ -protein radical adduct and prevents reaction with a second  $\text{CCl}_3\cdot$  radical:



Clearly,  $\alpha$ -tocopherol is primarily an antioxidant and only very high concentrations can significantly modify covalent binding of [<sup>14</sup>C]-CCl<sub>4</sub> metabolites. Nevertheless, the present study has shown that very high doses of  $\alpha$ -tocopherol, as used in some experimental models, may not necessarily discriminate between those cytotoxic effects dependent on lipid peroxidation and those dependent on covalent binding unlike the situation observed with promethazine.<sup>1,3</sup> The method of pre-treatment used here can inhibit CCl<sub>4</sub>-stimulated lipid peroxidation *in vivo*<sup>5</sup> and protects against CCl<sub>4</sub>-induced liver necrosis *in vivo*.<sup>6</sup> Since the levels of hepatic  $\alpha$ -tocopherol vary considerably using this method it may be of benefit to repeat these experiments *in vivo* simultaneously measuring parameters of lipid peroxidation, covalent binding and cell damage and relating them to actual  $\alpha$ -tocopherol concentrations.

### Acknowledgements

K. H. Cheeseman and S. Emery are supported by the Cancer Research Campaign. M.J. Davies is supported by the National Foundation for Cancer Research.

### References

1. Slater, T.F. in *Free Radicals, Lipid Peroxidation and Cancer*, eds. D.C.H. McBrien and T.F. Slater (Academic Press, London, 1982) p 243.
2. Cheeseman, K.H., Albano, E.F., Tomasi, A. and Slater, T.F. *Environ. Health Perspectives*, **64**, 85, (1985).
3. Dianzani M.U. and Poli, G. in *Free Radicals in Liver Injury*, eds. G. Poli, K.H. Cheeseman, M.U. Dianzani, and T.F. Slater (IRL Press, Oxford, 1985), p 149.
4. Cheeseman, K.H., Collins, M.M., Proudfoot, K.P., Slater, T.F., Burton, G.W., Webb, A.C. and Ingold, K.U. *Biochem. J.*, **235**, 507, (1986).
5. Corongiu, F.P., Dessi, M.A., Vargioulu, S., Poli, G., Cheeseman, K.H., Dianzani, M.U. and Slater, T.F. in *Free Radicals in Liver Injury*, eds. G. Poli, K.H. Cheeseman, M.U. Dianzani and T.F. Slater (IRL Press, Oxford, 1985) p 81.
6. Poli, G., Albano, E., Biasi, F., Cecchini, G., Carini, R., Bellomo, G. and Dianzani, M.U. in *Free Radicals in Liver Injury*, eds. G. Poli, K.H. Cheeseman, M.U. Dianzani and T.F. Slater (IRL Press, Oxford, 1985) p 207.
7. Pfeifer, P.M. and McCay P.B. *J. Biol. Chem.*, **246**, 6401, (1971).
8. Slater, T.F. and Sawyer, B.C. *Biochem. J.*, **111**, 317, (1969).
9. Slater T.F. and Sawyer, B.C. *Biochem. J.*, **123**, 805, (1971).
10. Cheeseman, K.H., Lai, M. and Slater, T.F. *IRCS Med. Sci.*, **9**, 600, (1981).
11. K.H. Cheeseman, *IRCS Med. Sci.*, **12**, 306, (1984).
12. Slater, T.F. *Biochem. J.*, **106**, 155, (1968).
13. Burton, G.W., Webb, A. and Ingold, K.U. *Lipids*, **20**, 29, (1985).
14. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. *J. Biol. Chem.*, **193**, 265, (1951).
15. Milia, A., Cheeseman, K.H., Forni, L.G., Willson, R.L., Corongiu, F.P. and Slater, T.F. *Biochem. Pharmacol.*, **34**, 437, (1985).
16. Burton, G.W., Cheeseman, K.H., Doba, T., Ingold, K.U. and Slater, T.F. in *Biology of Vitamin E* (Ciba Foundation Symposium 101, Pitman Books, London, 1983) p 4.
17. Packer, J.E., Slater, T.F. and Willson, R.L. *Nature*, **278**, 737, (1979).
18. Forni, L.G., Packer, J.E., Slater, T.F. and Willson, R.L. *Chem. Biol. Interact.*, **45**, 171, (1983).

19. Benedetti, A., Ferrali, M., Chieli, E. and Comporti, M. *Chem. Biol. Interact.*, **9**, 117, (1974).
20. McCay, P.B., King, M.M., Lai, E.K. and Poyer, J.L. *J. Am. Coll. Toxicol.*, **3**, 195, (1983).
21. Albano, E., Lott, K.A.K., Slater, T.F., Stier, A., Symons M.C.R. and Tomasi, A. *Biochem. J.*, **204**, 593, (1982).

**Accepted by Prof. H. Sies**